MAFLD: What Is It?

Houston Methodist

D. Victor

Contrast Nephropathy

ARCH Advanced Revascularization Symposium

Preoperative Risk Assessment for Patients with Liver Disease

Rush University Medical Center

S. Repking

Best Practices In Managing NAFLD / NASH

MedNews Week

D. Bernstein

Pharmacologic Management of Alcohol Use Disorder

Scripps Health

R. Lee

Important Safety Information - Off-Target Effects of New Therapies f…

Ronald Goldenberg

Major Advancements in MASH Management

Rush University Medical Center

S. Janardhan

The Fatty Liver Disease Epidemic

UPMC

M. Klinge

Updates in Management for Patients with Cirrhosis

Duke Health

R. Doshi

Alcoholism is a Mid-brain Disease: Treat it as Such

Houston Methodist

H. Wetsman

Sepsis and AKI - DAMPS & PAMPS

IRRIV International Renal Research Institute Vicenza

C. Ronco

Using Resmetirom (THR-β Agonist) in Your Practice for MASH

Scripps Health

J. Gutierrez

New Therapy for Fatty Liver Disease

Washington University in St. Louis

K. Korenblat

Alcohol Use Disorder (2024)

UCSF School of Medicine

T. Defries

MetALD: What Is It, and How Do We Manage It?

Rush University Medical Center

L. Ritchie

Updates in Nephrology

University of Colorado Department of Medicine

A. Jovanovich

MASLD Updates Early 2025

Adrian Lindsey

Proton Pump Inhibitors: Debunking Media Myths

Houston Methodist

C. Kim

Cutting Edge Diagnostics and Treatment for NAFLD

Northwestern Medicine Gastroenterology

M. E. Rinella, L. Van Wagner

Fatty Liver Disease: When to Refer?

Yale School of Medicine